MEDVi GLP-1 Weight Loss Program: Insurance-Free Access to Doctor-Led Semaglutide and Tirzepatide
As interest in GLP-1–based weight loss treatments continues to increase in 2026, a growing number of consumers are looking for a trusted GLP-1 supplier that combines affordability, appropriate medical oversight, and flexible access. With brand-name GLP-1 medications frequently costing between $1,300 and $1,500 per month without insurance coverage, pricing remains a significant obstacle for many individuals.
MEDVi, LLC operates a U.S.-based telehealth platform designed to facilitate access to compounded semaglutide for weight management. Based on pricing details published on the official website, MEDVi lists introductory pricing for compounded semaglutide at $179 for the first month, followed by $299 for ongoing monthly refills. The platform provides both compounded GLP-1 injectable options and oral tablet formulations, offered on a month-to-month basis without long-term contractual commitments.
According to company statements, more than 100,000 patients have used the MEDVi platform, reflecting the broader expansion of telehealth-based weight loss services as consumers seek lower-cost GLP-1 access in advance of the New Year weight loss period.
Overview of the MEDVi Telehealth GLP-1 Platform
When evaluating a potential GLP-1 supplier, consumers often consider factors beyond cost alone. MEDVi operates under a defined structure that separates technology services, clinical decision-making, and medication fulfillment.
- MEDVi, LLC delivers the digital platform, patient intake tools, administrative coordination, customer service, and payment processing.
- Licensed medical providers, affiliated with OpenLoop Health, review patient-submitted health information and determine prescription eligibility.
- Partner compounding pharmacies prepare and dispense medications based on prescriptions issued by licensed clinicians.
Enrollment and payment through the platform do not ensure that a prescription will be issued. All prescribing decisions are made independently by licensed healthcare professionals following an evaluation of individual medical history and clinical appropriateness.
MEDVi’s published terms specify that the company itself does not provide medical care and is not licensed to practice medicine. All healthcare services are delivered by independent medical providers.
The MEDVi platform operates on a month-to-month basis with no contractual obligation, as outlined on the company website. Readers seeking additional context may review a more detailed platform analysis available online.
Understanding MEDVi’s Three-Entity Operating FrameworkMEDVi, LLC: Platform and Administrative Operations
MEDVi functions primarily as a technology and coordination provider, rather than as a healthcare entity. Its responsibilities include operating the telehealth platform, supporting communication between patients and clinicians, managing billing processes, and addressing non-clinical support requests. Any medical inquiries are directed to licensed providers within the OpenLoop Health network.
Business Address:
131 Continental Dr, Suite 305, Newark, DE 19713
Contact Information:
help@medvi.org | (323) 690-1564
OpenLoop Health: Licensed Medical Provider Network
OpenLoop Health supports a network of U.S.-licensed physicians who assess patient health information and determine whether compounded GLP-1 medications, including semaglutide, are medically appropriate. Prescribing authority remains exclusively with licensed clinicians, and approvals are issued on an individual, case-by-case basis.
While MEDVi references certain physicians in its educational materials, the platform does not publicly disclose the full scope of its provider network or detailed state-by-state licensure information. Provider credentials can be independently verified using public state medical board databases.
Partner Compounding Pharmacies
According to platform disclosures, MEDVi collaborates with multiple U.S.-certified compounding pharmacies to fulfill prescriptions. The company reports ongoing communication with pharmacy partners regarding medication availability, quality assurance testing, and shipping schedules.
The names of specific pharmacies are not publicly listed but may be requested from customer support prior to enrollment.
Is MEDVi a Reliable GLP-1 Supplier for You?
Determining whether a platform qualifies as a reliable GLP-1 supplier depends on several individual factors, including personal weight loss goals, medical history, budget considerations, and comfort with telehealth-based care models. MEDVi presents itself as a platform centered on transparent pricing, independent clinical evaluation, and flexible month-to-month participation without long-term commitments.
Individuals considering whether MEDVi is appropriate for their weight loss objectives can review current pricing, available medication formats, and enrollment information directly on the platform. As with any GLP-1 treatment program, both eligibility and outcomes are contingent on evaluation and approval by a licensed medical provider.
FDA-Approved vs Compounded GLP-1 Medications
Understanding the regulatory distinction between FDA-approved GLP-1 medications and compounded GLP-1 formulations is an important step for individuals researching weight loss options in 2026. These two categories differ substantially in approval processes, clinical evidence requirements, manufacturing oversight, and insurance coverage.
FDA-Approved GLP-1 Medications for Weight Loss
FDA-approved GLP-1 receptor agonists indicated for chronic weight management include Wegovy, which contains semaglutide, and Saxenda, which contains liraglutide. Ozempic, also formulated with semaglutide, is approved by the FDA for the treatment of type 2 diabetes but may be prescribed off-label for weight loss when a licensed clinician determines it is medically appropriate.
Under FDA regulations, physicians are permitted to prescribe approved medications for off-label use based on their professional medical judgment. When Ozempic is used specifically for weight management, it is classified as an off-label prescription.
Clinical Trial Evidence Supporting Wegovy
The FDA approval of Wegovy was based on large, randomized clinical trials, including the STEP 1 study, which evaluated weight loss outcomes in adults with obesity or overweight plus related health conditions. Key findings from the trial included:
- 1,961 adult participants
- 68-week study duration
- Average weight loss of approximately 9% of body weight
- 86% of participants lost at least 5% of body weight
- 69% lost at least 10%
- 50% lost at least 15%
- Participants followed reduced-calorie diets and increased physical activity
Prior to FDA approval, GLP-1 medications completed Phase I, Phase II, and Phase III clinical trials. The FDA evaluated each product’s safety profile, effectiveness, manufacturing standards, and labeling accuracy. Following approval, ongoing post-market surveillance continues to monitor long-term safety outcomes.
Pricing and Insurance Coverage for FDA-Approved GLP-1 Medications
Retail pricing for FDA-approved GLP-1 weight loss medications typically ranges from $1,300 to $1,500 per month without insurance coverage. Most private insurance plans do not cover weight loss medications, and Medicare and Medicaid generally exclude coverage for these treatments.
Compounded GLP-1 Medications
Compounded GLP-1 medications operate under a different regulatory framework than FDA-approved drugs. According to MEDVi’s published terms, compounded formulations are not reviewed or approved by the FDA as finished products. These medications are prepared by licensed compounding pharmacies using active ingredients sourced from FDA-registered manufacturers and are dispensed only under a clinician’s prescription.
FDA Guidance on Compounded Medications
The FDA states that compounded drugs are not evaluated for safety, effectiveness, or quality prior to distribution. Compounding is generally intended for circumstances in which FDA-approved medications are unavailable or when a patient has a specific medical need that cannot be addressed by approved products.
Compounding pharmacies operate under two primary regulatory pathways:
- Section 503A applies to state-licensed pharmacies compounding medications for individual patients
- Section 503B applies to FDA-registered outsourcing facilities that compound medications in bulk
FDA Safety Alerts Related to Compounded Semaglutide
The FDA has issued safety communications regarding dosing errors associated with compounded semaglutide, particularly when provided in multi-dose vials. Errors may occur if patients misunderstand unit conversions or dosing instructions.
Patients are advised to carefully follow dosing guidance provided by their prescribing clinician and compounding pharmacy and to seek clarification immediately if instructions are unclear.
MEDVi GLP-1 Medication Options and Current Pricing
Based on information published on the MEDVi website, the platform currently provides the following GLP-1 medication options:
- Compounded GLP-1 injections (weekly): Introductory pricing begins at $179 for the first month, with ongoing refills listed at $299 per month as of December 19, 2025.
- Compounded GLP-1 tablets (daily dissolvable): Priced at $249 for the first month, with refill pricing available upon request through customer support.
- Brand-name Ozempic: Listed at $1,999 per month when inventory is available through the platform.
Differences in Clinical Evidence and Product Consistency
FDA-approved semaglutide medications are supported by extensive clinical trial data involving thousands of participants. While compounded semaglutide contains the same active ingredient, it has not undergone independent clinical trials as a finished pharmaceutical product.
Although many compounding protocols are designed to follow FDA-approved dosing guidelines, quality controls, testing procedures, and batch consistency may differ across compounding pharmacies.
MEDVi Pricing Model, Costs, and Payment Overview
Evaluating the overall pricing structure, payment responsibilities, and related considerations is an important step for individuals assessing compounded GLP-1 weight loss programs. The following information reflects publicly available disclosures from MEDVi.
Compounded GLP-1 Medication Pricing Details
According to MEDVi’s official website, pricing for compounded GLP-1 medications is structured as follows:
Compounded GLP-1 Injections
- First month: $179
Included services listed on the website encompass physician evaluation, personalized treatment planning, one-on-one guidance, metabolic reporting, prescription medication, and shipping. - Monthly refills: $299 per month
Pricing reflects published listings as of December 19, 2025. - Estimated annual cost:
- First year: Approximately $3,468, calculated as $179 plus eleven months at $299
- Subsequent years: Approximately $3,588, based on twelve months at $299
Compounded GLP-1 Tablets
- First month: $249
- Refill pricing: Not clearly listed and should be confirmed with customer support prior to enrollment.
Brand-Name GLP-1 Medication Pricing
- Ozempic: Listed starting at $1,999 per month when available through the MEDVi platform.
Cancellation Policy and Refund Considerations
MEDVi states that its program operates on a month-to-month basis with no long-term contractual obligation. Refund eligibility is determined by the outcome of the clinical evaluation and whether medication has already been prepared or shipped.
Because refund determinations vary by individual circumstances, prospective patients are encouraged to review the full cancellation and refund policy on the company website prior to enrollment.
Insurance Status and Patient Payment Responsibility
According to company disclosures, MEDVi-affiliated medical providers are not contracted with commercial or government insurance plans and are considered out-of-network. Patients are responsible for 100% of program costs.
Medicare and Medicaid are not accepted, and insurance reimbursement is not available for services provided through the platform.
HSA and FSA Payment Eligibility
MEDVi marketing materials indicate that HSA and FSA payments may be accepted. Under IRS guidelines, prescription medications and medical services ordered by licensed providers are generally eligible expenses. Final eligibility, however, is determined by individual plan administrators.
Patients are advised to confirm coverage directly with their HSA or FSA provider before using these funds.
For the most up-to-date pricing or enrollment inquiries, individuals may visit the MEDVi website or contact customer support at (323) 690-1564.
How GLP-1 Therapies Function in Weight Management
GLP-1, short for glucagon-like peptide-1, is a hormone naturally produced in the intestines that plays an important role in appetite regulation and blood glucose control. GLP-1 receptor agonist medications, including semaglutide, are engineered to resist rapid breakdown in the body, which allows them to remain active for longer periods.
These medications promote weight loss by activating appetite-regulating pathways in the brain, slowing gastric emptying, and enhancing glucose-dependent insulin secretion, which together help reduce caloric intake and support metabolic control.
Clinical Evidence and Anticipated Weight Loss ResultsTrial Data for FDA-Approved Semaglutide
Clinical trial findings for FDA-approved semaglutide provide useful benchmarks for expected outcomes. Key results include:
- The STEP 1 trial demonstrated an average weight loss of approximately 9% over 68 weeks when semaglutide was combined with reduced-calorie diets and increased physical activity.
- Outcomes varied, with roughly half of participants not reaching a 15% weight loss threshold.
- The STEP 2 trial, which included individuals with type 2 diabetes, reported an average weight loss of approximately 6%.
These studies highlight both the potential effectiveness of semaglutide and the variability in individual response.
Context for Compounded Semaglutide Outcomes
Compounded semaglutide formulations have not been evaluated in large-scale independent clinical trials as finished products. According to disclosures on the MEDVi website, patients using compounded semaglutide typically experience weight loss of approximately one to two pounds per week after the first four weeks, when combined with dietary adjustments and lifestyle changes.
Individual results vary based on factors such as starting weight, metabolic health, adherence to nutrition and activity recommendations, genetic influences, and concurrent medications.
Safety Overview and Medical Considerations
GLP-1 medications are prescription-strength pharmaceutical agents. The information provided here is intended for general education and does not replace official prescribing information or personalized medical advice.
Commonly Reported Side Effects
Research on semaglutide indicates that gastrointestinal symptoms are the most frequently reported side effects. These may include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Other reported effects include fatigue, headaches, dizziness, and injection site reactions for injectable formulations. Symptoms are often mild to moderate and may lessen with continued use.
Patients who experience persistent or severe symptoms are advised to contact their prescribing provider.
Serious but Infrequent Risks
Although uncommon, more serious risks have been reported. These include thyroid tumors observed in animal studies, acute pancreatitis, gallbladder disease associated with rapid weight loss, kidney function impairment related to dehydration, hypoglycemia when combined with certain diabetes medications, and severe allergic reactions.
Contraindications and Cautionary Use
GLP-1 medications are not recommended for individuals with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, known hypersensitivity to semaglutide, or for those who are pregnant or breastfeeding. Additional caution is advised for patients with a history of pancreatitis, gallbladder disease, kidney disease, diabetic retinopathy, or gastrointestinal motility disorders.
Considerations Specific to Compounded Medications
MEDVi advises patients to discuss the risks and benefits of compounded medications directly with their prescribing clinician. Variations in compounding methods, storage requirements, bioavailability, and batch consistency may occur between pharmacies.
This overview does not replace Patient Drug Education materials or official prescribing documentation. Patients should review all safety information included with their prescription and consult their healthcare provider or pharmacist with any questions.
Compounded GLP-1 Market Landscape and Competitive Environment
The market for compounded GLP-1 weight loss treatments has expanded rapidly as consumers seek alternatives to FDA-approved medications that often involve high retail pricing and limited insurance coverage. In response, numerous telehealth platforms now offer compounded semaglutide through operating models that separate technology platforms, licensed medical providers, and compounding pharmacies.
Across the sector, monthly refill pricing typically ranges from $250 to $400. MEDVi operates within this competitive range, where affordability, access, and month-to-month flexibility are key factors influencing consumer decisions.
Industry analysts identify three primary drivers behind the growth of compounded GLP-1 programs: limited insurance coverage for weight loss medications, continued high retail pricing for FDA-approved GLP-1 drugs, and increased consumer acceptance of telehealth prescription services following widespread adoption during the pandemic. As a result, platforms in this space often emphasize transparent pricing, digital intake workflows, and remote medical oversight.
At the same time, the compounded GLP-1 category is attracting increased regulatory scrutiny, creating a competitive landscape where differentiation increasingly depends on pricing structure, medication format availability, and operational transparency regarding clinical decision-making.
Assessing Patient Eligibility and Treatment Considerations
Determining whether MEDVi’s telehealth-based GLP-1 program is an appropriate option depends on several factors, including medical eligibility, financial readiness, and individual treatment preferences. As with any prescription-based weight loss approach, suitability varies from person to person.
Individuals Who May Be Well Suited to the MEDVi Platform
Certain individuals may find MEDVi’s model aligns with their needs and circumstances:
- Seeking lower-cost GLP-1 access without insurance
For patients whose insurance plans do not cover weight loss medications, MEDVi’s listed refill pricing of $299 per month for compounded injections represents a more affordable alternative compared to FDA-approved GLP-1 medications, which commonly retail between $1,300 and $1,500 per month. - Comfortable with compounded medication frameworks
Some individuals understand that compounded semaglutide is not FDA-approved as a finished product and accept this regulatory distinction in exchange for reduced monthly costs. - Preference for fully remote medical care
A telehealth-only model may appeal to individuals facing time constraints, transportation challenges, or those who value privacy and convenience when managing their care. - Relatively uncomplicated medical histories
Patients who are otherwise healthy aside from obesity or common weight-related conditions such as prediabetes or controlled high blood pressure may be appropriate candidates for telehealth-based supervision.
Individuals Who May Require Alternative Approaches
In some cases, alternative treatment options or closer in-person monitoring may be more appropriate:
- Preference for FDA-approved medications only
Some individuals choose treatments that have completed full FDA review and extensive clinical trials as finished pharmaceutical products. - Presence of complex or high-risk medical conditions
Patients with unstable cardiovascular disease, advanced kidney disease, recurrent pancreatitis, gastroparesis, or complex medication regimens may require more comprehensive in-person oversight. - Low tolerance for gastrointestinal side effects
GLP-1 medications frequently cause nausea, vomiting, and other digestive symptoms that may persist for weeks or months in some individuals. - Expectation of results without lifestyle modification
Although GLP-1 therapies reduce appetite, sustainable weight loss typically requires dietary changes and increased physical activity.
Limitations of Telehealth-Based Care
Telehealth weight loss programs differ from in-person medical care in several important ways. Remote providers are unable to conduct physical examinations, directly measure vital signs, or manage emergency situations.
According to platform disclosures, MEDVi is intended for non-emergency medical needs only. Individuals experiencing urgent or life-threatening symptoms are advised to contact emergency services or seek immediate local medical care.
Platform Verification and Legitimacy Overview
Corporate Registration and Business Details
MEDVi operates as a legally registered limited liability company in the state of Delaware. Its registration status can be verified through the Delaware Division of Corporations public database.
- Legal entity: MEDVi, LLC
- Business address: 131 Continental Dr, Suite 305, Newark, DE 19713
Public Contact Information
MEDVi provides publicly accessible contact details for inquiries related to enrollment, billing, and platform services:
- Email: help@medvi.org
- Phone: (323) 690-1564
Medical Provider Credential Verification
Medical evaluations and prescribing decisions are handled through the OpenLoop Health provider network. Patients may independently verify clinician credentials and license status using publicly available state medical board databases, which maintain current licensure records.
Prescribing authority resides solely with licensed medical professionals, not with the MEDVi technology platform.
Payment Processing and Data Security
According to platform terms, payment transactions are processed via Stripe, a widely used payment processor that employs industry-standard security measures, including encryption and fraud prevention systems, to protect financial information.
Compliance and Legal Documentation
MEDVi’s published terms of use include documentation addressing key compliance areas such as HIPAA privacy protections, telehealth informed consent requirements, disclosures regarding the regulatory status of compounded medications, mandatory arbitration provisions, and limitations of liability.
Prospective patients are encouraged to review these materials carefully prior to enrollment. Individuals seeking additional details about MEDVi’s operating structure, pricing, or provider coordination may visit the company website or contact customer support at (323) 690-1564.
Regulatory Landscape and Ongoing Industry Oversight
According to company disclosures, telehealth-based weight loss programs and prescription compounding services have been subject to increasing regulatory scrutiny in recent years. Patients are encouraged to review the most up-to-date information regarding a platform’s compliance status and regulatory standing before initiating treatment.
The FDA continues to issue and update guidance related to medication compounding practices, while state pharmacy boards have expanded oversight of compounding operations at the state level. As regulatory frameworks evolve, platforms operating within current guidelines may be required to meet additional compliance obligations. Patients may also reference the FDA drug shortage database to review the current availability status of semaglutide.
Personal Factors to Consider When Evaluating Treatment Options
Determining whether MEDVi’s platform structure and GLP-1 treatment offerings are appropriate depends on several individual considerations:
- Medical suitability
Presence of contraindications such as a personal or family history of thyroid cancer, Multiple Endocrine Neoplasia type 2, prior pancreatitis, or severe kidney disease. Patients should also consider potential drug interactions and whether they have discussed GLP-1 therapy with a primary care provider. - Financial preparedness
Ability to maintain monthly costs of approximately $299 over an extended treatment period, along with a clear understanding of refund policies and cancellation terms. - Lifestyle commitment
Willingness to implement dietary changes and increase physical activity while managing potential side effects alongside work and daily responsibilities. - Expectation management
Awareness that weight loss is typically gradual, often averaging one to two pounds per week, and that outcomes vary significantly among individuals. - Risk tolerance
Comfort with the regulatory status of compounded medications, which are prepared using FDA-registered facilities but are not FDA-approved as finished products and have not undergone independent clinical trials.
Final treatment decisions are made by licensed clinicians based on individual medical history, clinical evaluation, and professional judgment. Providers determine whether compounded formulations or alternative treatment pathways are appropriate for each patient.
Contact Details and Further Information
Based on information published on the MEDVi website, individuals seeking additional details may use the following contact information:
- Email: help@medvi.org
- Phone: (323) 690-1564
- Address: 131 Continental Dr, Suite 305, Newark, DE 19713
Additional information regarding current programs, pricing, and enrollment options is available through the official website.
Disclaimer
This content is provided for informational and educational purposes only and does not constitute medical, legal, or financial advice. It is not intended to diagnose, treat, cure, or prevent any disease. Prescription medications, including GLP-1 therapies, require evaluation and authorization by a licensed healthcare professional based on individual medical history and clinical judgment. Compounded medications are not FDA-approved as finished products and may differ from FDA-approved drugs in formulation, testing, and oversight. Individual results and experiences may vary. Always consult a qualified healthcare provider before starting, stopping, or modifying any medication or weight loss program. Pricing, availability, and policies are subject to change.
Latest Articles
